Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402763 | 0.84 | ALDH1A1 (0.55) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL28474124 | 0.83 | MEN1 (0.74) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6139630 | 0.82 | MAPT (1.00) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL9210472 | 0.82 | MAPT (0.67) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL6218138 | 0.82 | MAPT (0.67) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL16052890 | 0.81 | MEN1 (0.65) | MAPTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL5931364 | 0.81 | MEN1 (1.00) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL11048818 | 0.79 | MAPT (0.62) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1162890 | 0.79 | MAPT (0.62) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL8844390 | 0.78 | ALDH1A1 (0.64) | MAPTMEN1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-09-26 | — | — | US | disclosed |
| US-6844337-B2 | 1,4-diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, their preparation and their application in therapeutics | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| EP-1289986-B1 | 1,4-DIAZABICYCLO 3.2.2]NONANE-PHENYLISOXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-04-28 | — | — | EP | disclosed |
| US-20030114461-A1 | 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114461-A1 | 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof | CYC1, GLRA1, CBR1 | MAPT 4765/4885MEN1 1537/4885KMT2A 3489/4885 |
| US-11767297-B2 | Compounds for inhibiting TNIK and medical uses thereof | TNNI3K, TNK1, TNIK | MAPT 3588/4885MEN1 2818/4885KMT2A 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.